European regulators granted market approval for Merck KGaA and Pfizer’s immuno-oncology drug Bavencio to treat a rare and aggressive type of skin cancer called Merkel cell carcinoma.
The Centers for Disease Control and Prevention has been using multiple channels to get the word out about post-storm safety to residents of areas still reeling from the effects of recent hurricanes.
Arcus Biosciences announced it has inked an option and license deal with Taiho Pharmaceutical Co. to develop and commercialize product candidates in Arcus’s portfolio in Japan and specific Asian territories excluding China.
Indianapolis-based Eli Lilly continues to make the case for cyclin-dependent kinases inhibitors, particularly CDK4 and CDK6, as an effective treatment of cancers.
Positive Phase III data were reported for Alnylam’s RNA interference treatment for hereditary ATTR amyloidosis with polyneuropathy.
Shire Plc and Shionogi & Co. Ltd. said a drug to treat ADHD in adults had met its main goal in a late-stage trial in Japan, bringing it one step closer to approval in the world’s third-biggest market for ADHD treatments.
Swiss drugmaker Novartis won European Union approval for Rydapt to be used against a mutated form of acute myeloid leukemia (AML) and other rare diseases.
Bristol-Myers Squibb’s immunotherapy drug Opdivo was recommended for some patients with lung cancer by Britain’s healthcare cost watchdog NICE after the drugmaker agreed a discounted price.
An FDA advisory committee voted 6 in favor and 6 against the benefit-risk profile for Pfizer’s Sutent as adjuvant treatment of adults at high risk of recurrent RCC after nephrectomy.
Ipsen Receives Approval from European Commission for Xermelo for the Treatment of Carcinoid Syndrome Diarrhea in Patients Inadequately Controlled by Somatostatin Analogue Therapy
Ipsen today announced that the European Commission approved Xermelo (telotristat ethyl) 250 mg three times a day for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analogue (SSA) therapy in adults inadequately controlled by SSA therapy.